首页 > 最新文献

Clinical Infectious Diseases最新文献

英文 中文
Tolerance, Not Resistance: Implications for Treatment Duration and Selective Test-of-Cure. 耐受性,而非耐药性:对治疗时间和选择性治愈试验的影响。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciaf457
Sheeba Santhini Manoharan-Basil, Chris Kenyon
{"title":"Tolerance, Not Resistance: Implications for Treatment Duration and Selective Test-of-Cure.","authors":"Sheeba Santhini Manoharan-Basil, Chris Kenyon","doi":"10.1093/cid/ciaf457","DOIUrl":"10.1093/cid/ciaf457","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"e745-e746"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Effectiveness of Ceftriaxone Monotherapy and Limited Value of Routine Test-of-Cure for Gonorrhea in a Low-Resistance Setting. 头孢曲松单药治疗在低耐药性环境下淋病的高疗效和常规治愈试验的有限价值。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciaf456
Chiara Fusetti, Federica Salari, Francesco Petri, Alberto Rizzo, Andrea Giacomelli, Andrea Cavallo, Francesco Caruso, Loriana Morelli, Cristina Gervasoni, Davide Mileto, Maria Vittoria Cossu, Alessandra Lombardi, Agostino Riva, Andrea Gori, Davide Moschese
{"title":"High Effectiveness of Ceftriaxone Monotherapy and Limited Value of Routine Test-of-Cure for Gonorrhea in a Low-Resistance Setting.","authors":"Chiara Fusetti, Federica Salari, Francesco Petri, Alberto Rizzo, Andrea Giacomelli, Andrea Cavallo, Francesco Caruso, Loriana Morelli, Cristina Gervasoni, Davide Mileto, Maria Vittoria Cossu, Alessandra Lombardi, Agostino Riva, Andrea Gori, Davide Moschese","doi":"10.1093/cid/ciaf456","DOIUrl":"10.1093/cid/ciaf456","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"e744-e745"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline Antithrombotic Therapy and Intracranial Hemorrhage Risk in Infective Endocarditis: A Multicenter Prospective Cohort Study 感染性心内膜炎的基线抗血栓治疗和颅内出血风险:一项多中心前瞻性队列研究
IF 11.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciag067
Javier T Solera, Eduardo Aparicio-Minguijón, Laura Domínguez-Pérez, Patricia Muñoz, Pilar Vázquez-Alen, Ana Álvarez-Uría Miyares, Arístides de Alarcón, Manuel Poyato-Borrego, M Carmen Fariñas, José María Miró, Miguel Ángel Goenaga-Sánchez, Guillermo Ojeda-Burgos, Luis Eduardo López-Cortés, Dolores Sousa-Regueiro, Francisco López-Medrano
Background Infective endocarditis (IE) carries high morbidity and mortality, largely from neurological complications. The clinical significance of chronic antithrombotic therapy remains uncertain. We assessed whether baseline antithrombotic therapy influences intracranial hemorrhage (ICH) and mortality in left-sided IE. Methods We analyzed a prospective multicenter cohort (2008–2018) including all patients with definite left-sided IE. Patients were classified at diagnosis as receiving no therapy (NT), antiplatelet therapy (APT), anticoagulation (AC), or combined therapy (CAT). The primary outcome was 30-day ICH; secondary outcomes included ischemic stroke, embolic events, major bleeding, and all-cause mortality. Multivariable logistic and Cox regression models adjusted for confounders. Results Among 3,236 patients, 182 (5.6%) developed ICH, with the highest incidence in CAT (9.5%) and AC (6.8%). Compared with NT, baseline AC was independently associated with a higher frequency of ICH (adjusted risk ratio [aRR] 1.83, 95% CI 1.16–2.91), with the highest risk observed in CAT (aRR 2.45, 95% CI 1.55–3.87). APT was not associated with ICH. Ischemic stroke rates were similar across groups. CAT independently predicted higher 1-year mortality (adjusted hazard ratio [aHR] 1.21, 95% CI 1.02–1.43). Independent factors associated with ICH were Staphylococcus aureus and Candida spp. IE, extracranial embolism, prior cerebrovascular disease, and septic shock. Conclusions These findings highlight the value of baseline antithrombotic exposure, together with microbiologic etiology and prior cerebrovascular disease, for early neurologic risk stratification at the time of IE diagnosis, informing neuroimaging decisions and multidisciplinary discussions involving infectious diseases specialists, neurologist, and cardiac surgeons among other specialists.
背景:感染性心内膜炎(IE)具有很高的发病率和死亡率,主要由神经系统并发症引起。慢性抗血栓治疗的临床意义仍不确定。我们评估了基线抗栓治疗是否会影响左侧IE患者颅内出血(ICH)和死亡率。方法:我们分析了一个前瞻性多中心队列(2008-2018),包括所有明确的左侧IE患者。患者在诊断时被分为不接受治疗(NT)、抗血小板治疗(APT)、抗凝治疗(AC)或联合治疗(CAT)。主要结局为30天脑出血;次要结局包括缺血性中风、栓塞事件、大出血和全因死亡率。校正混杂因素的多变量logistic和Cox回归模型。结果3236例患者中,182例(5.6%)发生ICH,其中CAT(9.5%)和AC(6.8%)发生率最高。与NT相比,基线AC与较高的ICH发生频率独立相关(校正风险比[aRR] 1.83, 95% CI 1.16-2.91),其中CAT的风险最高(aRR 2.45, 95% CI 1.55-3.87)。APT与ICH无相关性。各组间缺血性卒中发生率相似。CAT独立预测较高的1年死亡率(校正风险比[aHR] 1.21, 95% CI 1.02-1.43)。与脑出血相关的独立因素有金黄色葡萄球菌、念珠菌、IE、颅外栓塞、既往脑血管疾病和感染性休克。这些发现强调了基线抗血栓暴露、微生物病因学和既往脑血管疾病对IE诊断时早期神经系统风险分层的价值,为神经影像学决策和涉及传染病专家、神经科医生和心脏外科医生等专家的多学科讨论提供了信息。
{"title":"Baseline Antithrombotic Therapy and Intracranial Hemorrhage Risk in Infective Endocarditis: A Multicenter Prospective Cohort Study","authors":"Javier T Solera, Eduardo Aparicio-Minguijón, Laura Domínguez-Pérez, Patricia Muñoz, Pilar Vázquez-Alen, Ana Álvarez-Uría Miyares, Arístides de Alarcón, Manuel Poyato-Borrego, M Carmen Fariñas, José María Miró, Miguel Ángel Goenaga-Sánchez, Guillermo Ojeda-Burgos, Luis Eduardo López-Cortés, Dolores Sousa-Regueiro, Francisco López-Medrano","doi":"10.1093/cid/ciag067","DOIUrl":"https://doi.org/10.1093/cid/ciag067","url":null,"abstract":"Background Infective endocarditis (IE) carries high morbidity and mortality, largely from neurological complications. The clinical significance of chronic antithrombotic therapy remains uncertain. We assessed whether baseline antithrombotic therapy influences intracranial hemorrhage (ICH) and mortality in left-sided IE. Methods We analyzed a prospective multicenter cohort (2008–2018) including all patients with definite left-sided IE. Patients were classified at diagnosis as receiving no therapy (NT), antiplatelet therapy (APT), anticoagulation (AC), or combined therapy (CAT). The primary outcome was 30-day ICH; secondary outcomes included ischemic stroke, embolic events, major bleeding, and all-cause mortality. Multivariable logistic and Cox regression models adjusted for confounders. Results Among 3,236 patients, 182 (5.6%) developed ICH, with the highest incidence in CAT (9.5%) and AC (6.8%). Compared with NT, baseline AC was independently associated with a higher frequency of ICH (adjusted risk ratio [aRR] 1.83, 95% CI 1.16–2.91), with the highest risk observed in CAT (aRR 2.45, 95% CI 1.55–3.87). APT was not associated with ICH. Ischemic stroke rates were similar across groups. CAT independently predicted higher 1-year mortality (adjusted hazard ratio [aHR] 1.21, 95% CI 1.02–1.43). Independent factors associated with ICH were Staphylococcus aureus and Candida spp. IE, extracranial embolism, prior cerebrovascular disease, and septic shock. Conclusions These findings highlight the value of baseline antithrombotic exposure, together with microbiologic etiology and prior cerebrovascular disease, for early neurologic risk stratification at the time of IE diagnosis, informing neuroimaging decisions and multidisciplinary discussions involving infectious diseases specialists, neurologist, and cardiac surgeons among other specialists.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"28 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary? 原生椎体骨髓炎的治疗保持不变:是否需要额外的试验?
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciag049
Werner Zimmerli
{"title":"The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary?","authors":"Werner Zimmerli","doi":"10.1093/cid/ciag049","DOIUrl":"https://doi.org/10.1093/cid/ciag049","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cycles of Susceptibility: Immunity Debt Explains Altered Infectious Disease Dynamics Post-Pandemic. 易感性循环:免疫债务解释了大流行后传染病动态的变化。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciae493
Alasdair P S Munro, Thomas House

The concept of immunity debt is a phenomenon resulting from the suppression of endemic pathogens during the COVID-19 pandemic due to non-pharmaceutical interventions. The reduced circulation of various pathogens during the pandemic, particularly respiratory syncytial virus (RSV), altered typical infectious disease dynamics by reducing levels of population immunity usually acquired through exposure to infection. This concept is demonstrated through the post-pandemic resurgence of diseases such as RSV and group A Streptococcus, and highlights the interplay between reduced pathogen exposure and increased susceptibility in populations. The complexities and nonlinear dynamics of seasonal transmission are observed in differences in pathogen resurgence across regions. These issues highlight the importance of comprehensive disease surveillance and public health strategies in mitigating these long-term epidemiological impacts.

免疫债务的概念是指在 COVID-19 大流行期间,由于非药物干预措施(NPI)抑制了地方性病原体而产生的一种现象。大流行期间,各种病原体(尤其是呼吸道合胞病毒(RSV))的循环减少,降低了通常通过接触感染获得的人群免疫力水平,从而改变了典型的传染病动态。大流行后,RSV 和 A 群链球菌等疾病的再次流行证明了这一概念,并强调了病原体暴露减少与人群易感性增加之间的相互作用。季节性传播的复杂性和非线性动态可从不同地区病原体复发的差异中观察到。这些问题凸显了全面疾病监测和公共卫生战略在减轻这些长期流行病学影响方面的重要性。
{"title":"Cycles of Susceptibility: Immunity Debt Explains Altered Infectious Disease Dynamics Post-Pandemic.","authors":"Alasdair P S Munro, Thomas House","doi":"10.1093/cid/ciae493","DOIUrl":"10.1093/cid/ciae493","url":null,"abstract":"<p><p>The concept of immunity debt is a phenomenon resulting from the suppression of endemic pathogens during the COVID-19 pandemic due to non-pharmaceutical interventions. The reduced circulation of various pathogens during the pandemic, particularly respiratory syncytial virus (RSV), altered typical infectious disease dynamics by reducing levels of population immunity usually acquired through exposure to infection. This concept is demonstrated through the post-pandemic resurgence of diseases such as RSV and group A Streptococcus, and highlights the interplay between reduced pathogen exposure and increased susceptibility in populations. The complexities and nonlinear dynamics of seasonal transmission are observed in differences in pathogen resurgence across regions. These issues highlight the importance of comprehensive disease surveillance and public health strategies in mitigating these long-term epidemiological impacts.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1173-1176"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Culture Time to Positivity and Risk of Infective Endocarditis. 血培养至阳性时间与感染性心内膜炎的风险。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciaf359
Sebastian D Santos-Patarroyo, Omar Abu Saleh, Supavit Chesdachai, Brian D Lahr, Hector I Michelena, Juan A Quintero-Martinez, Hector R Villarraga, Daniel C DeSimone, Larry M Baddour
{"title":"Blood Culture Time to Positivity and Risk of Infective Endocarditis.","authors":"Sebastian D Santos-Patarroyo, Omar Abu Saleh, Supavit Chesdachai, Brian D Lahr, Hector I Michelena, Juan A Quintero-Martinez, Hector R Villarraga, Daniel C DeSimone, Larry M Baddour","doi":"10.1093/cid/ciaf359","DOIUrl":"10.1093/cid/ciaf359","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"e732-e733"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Household Transmission and Genomic Diversity of Respiratory Syncytial Virus in the United States, 2022-2023. 2022-2023年美国呼吸道合胞病毒(RSV)的家庭传播和基因组多样性
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciaf048
Sarah N Cox, Pavitra Roychoudhury, Collrane Frivold, Zack Acker, Tara M Babu, Cassandra L Boisvert, Marco Carone, Brenna Ehmen, Janet A Englund, Leora R Feldstein, Luis Gamboa, Sally Grindstaff, Hanna M Grioni, Peter D Han, Katherine L Hoffman, Hyeong Geon Kim, Jennifer L Kuntz, Natalie K Lo, Christina M Lockwood, Kathryn McCaffrey, Richard A Mularski, Tara L Hatchie, Sacha L Reich, Mark A Schmidt, Ning Smith, Lea M Starita, Alexandra Varga, Neil Yetz, Allison L Naleway, Ana A Weil, Helen Y Chu

Background: Household transmission of respiratory viruses may drive community spread. Few recent studies have examined household respiratory syncytial virus (RSV) transmission in the United States.

Methods: We conducted a prospective community-based cohort study from 1 June 2022 to 31 May 2023. Participants had blood samples collected and completed nasal swabs and surveys at least weekly, irrespective of symptoms. We tested serum for RSV antibody, nasal swabs by quantitative reverse transcription polymerase chain reaction (RT-qPCR), and performed whole genome sequencing. We evaluated secondary RSV transmission and associated risk factors based on a log-linear Poisson regression model.

Results: RSV was detected among 310 (10%) participants within 200 (20%) households. Most (94%) index cases were symptomatic. We identified 37 cases of potential secondary transmission within 14 days of a distinct index case (10%, 95% confidence interval [CI]: 7%, 14%); median age of index and secondary cases were 6 (interquartile range [IQR]: 3-10) and 35 (7-41) years, respectively, with 89% (24/27) of index cases aged 6 months to 12 years. Factors associated with increased risk of RSV transmission included index case viral detection ≥1 week and contact age ≤12 years. Of 120 sequenced specimens, the main lineages represented were A.d.5.2 (n = 37) and A.d.1 (n = 30). Sequenced viruses from households with ≥2 RSV infections were similar when occurring within ≤14 days (mean pairwise difference 4 [range 0-13], n = 17 households), compared to those >14 days (137 [37-236], n = 2).

Conclusions: Most RSV household transmission occurs from infants and young children to adults. Viral genome sequencing demonstrated that multiple household infections within a 14-day period are likely due to within-household transmission.

背景:呼吸道病毒的家庭传播可能导致社区传播。最近很少有研究调查了美国家庭呼吸道合胞病毒(RSV)的传播。方法:我们从2022年6月1日至2023年5月31日进行了一项前瞻性社区队列研究。无论症状如何,参与者都收集了血液样本,并至少每周完成鼻拭子和调查。采用定量逆转录聚合酶链反应(RT-qPCR)检测血清RSV抗体、鼻拭子,并进行全基因组测序。我们基于对数线性泊松回归模型评估继发性RSV传播和相关危险因素。结果:200户(20%)家庭中有310名(10%)参与者检测到RSV。大多数(94%)指标病例有症状。我们在一个明显的指示病例后14天内确定了37例潜在的二次传播(10%,95%可信区间[CI]: 7%, 14%);指数病例和继发性病例的中位年龄分别为6岁(四分位间距[IQR]: 3-10岁)和35岁(7-41岁),其中89%(24/27)的指数病例年龄为6个月~ 12岁。与RSV传播风险增加相关的因素包括指数病例病毒检测≥1周和接触年龄≤12岁。在120个测序标本中,主要谱系为A.d.5.2 (n = 37)和A.d.1(n = 30)。来自≥2例RSV感染家庭的测序病毒在≤14天内与来自≥14天(137例[37-236],n = 2)发生的病毒相似(平均两两差异4[范围0-13],n = 17户)。结论:大多数RSV家庭传播发生在婴幼儿到成人之间。病毒基因组测序表明,14天内发生的多起家庭感染可能是由于家庭内部传播造成的。
{"title":"Household Transmission and Genomic Diversity of Respiratory Syncytial Virus in the United States, 2022-2023.","authors":"Sarah N Cox, Pavitra Roychoudhury, Collrane Frivold, Zack Acker, Tara M Babu, Cassandra L Boisvert, Marco Carone, Brenna Ehmen, Janet A Englund, Leora R Feldstein, Luis Gamboa, Sally Grindstaff, Hanna M Grioni, Peter D Han, Katherine L Hoffman, Hyeong Geon Kim, Jennifer L Kuntz, Natalie K Lo, Christina M Lockwood, Kathryn McCaffrey, Richard A Mularski, Tara L Hatchie, Sacha L Reich, Mark A Schmidt, Ning Smith, Lea M Starita, Alexandra Varga, Neil Yetz, Allison L Naleway, Ana A Weil, Helen Y Chu","doi":"10.1093/cid/ciaf048","DOIUrl":"10.1093/cid/ciaf048","url":null,"abstract":"<p><strong>Background: </strong>Household transmission of respiratory viruses may drive community spread. Few recent studies have examined household respiratory syncytial virus (RSV) transmission in the United States.</p><p><strong>Methods: </strong>We conducted a prospective community-based cohort study from 1 June 2022 to 31 May 2023. Participants had blood samples collected and completed nasal swabs and surveys at least weekly, irrespective of symptoms. We tested serum for RSV antibody, nasal swabs by quantitative reverse transcription polymerase chain reaction (RT-qPCR), and performed whole genome sequencing. We evaluated secondary RSV transmission and associated risk factors based on a log-linear Poisson regression model.</p><p><strong>Results: </strong>RSV was detected among 310 (10%) participants within 200 (20%) households. Most (94%) index cases were symptomatic. We identified 37 cases of potential secondary transmission within 14 days of a distinct index case (10%, 95% confidence interval [CI]: 7%, 14%); median age of index and secondary cases were 6 (interquartile range [IQR]: 3-10) and 35 (7-41) years, respectively, with 89% (24/27) of index cases aged 6 months to 12 years. Factors associated with increased risk of RSV transmission included index case viral detection ≥1 week and contact age ≤12 years. Of 120 sequenced specimens, the main lineages represented were A.d.5.2 (n = 37) and A.d.1 (n = 30). Sequenced viruses from households with ≥2 RSV infections were similar when occurring within ≤14 days (mean pairwise difference 4 [range 0-13], n = 17 households), compared to those >14 days (137 [37-236], n = 2).</p><p><strong>Conclusions: </strong>Most RSV household transmission occurs from infants and young children to adults. Viral genome sequencing demonstrated that multiple household infections within a 14-day period are likely due to within-household transmission.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1159-1169"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Diabetic Man With Fever, Cough, and Necrotic Eschar. 1例伴有发热、咳嗽和坏死痂的糖尿病患者。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciaf388
Zhi-Yuan Chen, Hao Guo
{"title":"A Diabetic Man With Fever, Cough, and Necrotic Eschar.","authors":"Zhi-Yuan Chen, Hao Guo","doi":"10.1093/cid/ciaf388","DOIUrl":"https://doi.org/10.1093/cid/ciaf388","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"81 6","pages":"1209-1211"},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutting federal funds for HIV testing means not Ending the HIV Epidemic. 削减用于艾滋病毒检测的联邦资金并不意味着终结艾滋病毒的流行。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciag039
Sarah E Scott, Joshua A Barocas
{"title":"Cutting federal funds for HIV testing means not Ending the HIV Epidemic.","authors":"Sarah E Scott, Joshua A Barocas","doi":"10.1093/cid/ciag039","DOIUrl":"https://doi.org/10.1093/cid/ciag039","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience. 原发性椎体骨髓炎的临床表现、长期趋势和治疗失败的危险因素:梅奥诊所26年的经验。
IF 7.3 1区 医学 Q1 IMMUNOLOGY Pub Date : 2026-02-04 DOI: 10.1093/cid/ciag048
Takahiro Matsuo, Fabio Borgonovo, Brian D Lahr, Francesco Petri, Rita Igwilo-Alaneme, Sergio L Alvarez Mulett, Seyed Mohammad Amin Alavi, Doug W Challener, Ahmad Nassr, Paul M Huddleston, Aaron J Tande, Elie F Berbari

Background: Native vertebral osteomyelitis (NVO) is a life-threatening spinal infection with rising incidence and significant morbidity. Despite its growing burden, long-term data on clinical characteristics, management trends, and outcomes remain limited.

Methods: We conducted a 26-year multicenter retrospective cohort study of adults (≥18 years) diagnosed with NVO at Mayo Clinic sites between 1999-2024. Demographic, microbiologic, treatment, and outcome data were analyzed across five time periods. Predictors of treatment failure were assessed using a multivariable competing risk model.

Results: Among 1,255 patients (median age 67; 66% male), lumbosacral involvement was most common (65%), and 21% had multilevel involvement. Pathogens were identified in 77%, most commonly S. aureus (49%; MSSA 37%, MRSA 13%). Over time from 1999-2004 to 2020-2024, Gram-negative bacilli increased from 6% to 14% (p=0.048).Comorbidities including chronic kidney disease (10% to 21%), active chemotherapy (6% to 11%), and immunosuppression (8% to 17%) increased significantly. Additionally, 1-year treatment failure declined (16% to 10%). In multivariable analysis, diabetes mellitus (sHR 1.92, 95% CI 1.18-3.13) and multilevel involvement (sHR 1.67, 95% CI 1.17-2.38) were associated with increased incidence of treatment failure, while concurrent infections (sHR 0.57, 95% CI 0.37-0.87) and higher Charlson Comorbidity Index (CCI) (sHR 0.62, 95% CI 0.43-0.90) were associated with lower failure.

Conclusion: This large multicenter cohort highlights increasing host complexity, shifting microbiology, and predictors of failure, emphasizing the importance of early risk stratification and tailored strategies, such as multidisciplinary evaluation and close follow-up of high-risk patients to improve outcomes.

背景:原发性椎体骨髓炎(NVO)是一种危及生命的脊柱感染,发病率和发病率均呈上升趋势。尽管其负担越来越大,但关于临床特征、管理趋势和结果的长期数据仍然有限。方法:我们对1999-2024年间梅奥诊所诊断为NVO的成人(≥18岁)进行了一项26年的多中心回顾性队列研究。人口统计学、微生物学、治疗和结局数据跨越五个时间段进行分析。使用多变量竞争风险模型评估治疗失败的预测因子。结果:在1255例患者中(中位年龄67岁,66%为男性),腰骶部受累最为常见(65%),21%为多节段受累。77%的病原菌被鉴定出来,最常见的是金黄色葡萄球菌(49%;MSSA 37%, MRSA 13%)。从1999-2004年到2020-2024年,革兰氏阴性杆菌从6%增加到14% (p=0.048)。合并症包括慢性肾脏疾病(10% - 21%)、积极化疗(6% - 11%)和免疫抑制(8% - 17%)显著增加。此外,1年治疗失败率下降(16%至10%)。在多变量分析中,糖尿病(sHR 1.92, 95% CI 1.18-3.13)和多水平介入(sHR 1.67, 95% CI 1.17-2.38)与治疗失败率增加相关,而并发感染(sHR 0.57, 95% CI 0.37-0.87)和较高的Charlson合并症指数(sHR 0.62, 95% CI 0.43-0.90)与治疗失败率降低相关。结论:这一大型多中心队列研究强调了宿主复杂性的增加、微生物学的变化和失败的预测因素,强调了早期风险分层和量身定制策略的重要性,如多学科评估和对高危患者的密切随访,以改善预后。
{"title":"Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience.","authors":"Takahiro Matsuo, Fabio Borgonovo, Brian D Lahr, Francesco Petri, Rita Igwilo-Alaneme, Sergio L Alvarez Mulett, Seyed Mohammad Amin Alavi, Doug W Challener, Ahmad Nassr, Paul M Huddleston, Aaron J Tande, Elie F Berbari","doi":"10.1093/cid/ciag048","DOIUrl":"https://doi.org/10.1093/cid/ciag048","url":null,"abstract":"<p><strong>Background: </strong>Native vertebral osteomyelitis (NVO) is a life-threatening spinal infection with rising incidence and significant morbidity. Despite its growing burden, long-term data on clinical characteristics, management trends, and outcomes remain limited.</p><p><strong>Methods: </strong>We conducted a 26-year multicenter retrospective cohort study of adults (≥18 years) diagnosed with NVO at Mayo Clinic sites between 1999-2024. Demographic, microbiologic, treatment, and outcome data were analyzed across five time periods. Predictors of treatment failure were assessed using a multivariable competing risk model.</p><p><strong>Results: </strong>Among 1,255 patients (median age 67; 66% male), lumbosacral involvement was most common (65%), and 21% had multilevel involvement. Pathogens were identified in 77%, most commonly S. aureus (49%; MSSA 37%, MRSA 13%). Over time from 1999-2004 to 2020-2024, Gram-negative bacilli increased from 6% to 14% (p=0.048).Comorbidities including chronic kidney disease (10% to 21%), active chemotherapy (6% to 11%), and immunosuppression (8% to 17%) increased significantly. Additionally, 1-year treatment failure declined (16% to 10%). In multivariable analysis, diabetes mellitus (sHR 1.92, 95% CI 1.18-3.13) and multilevel involvement (sHR 1.67, 95% CI 1.17-2.38) were associated with increased incidence of treatment failure, while concurrent infections (sHR 0.57, 95% CI 0.37-0.87) and higher Charlson Comorbidity Index (CCI) (sHR 0.62, 95% CI 0.43-0.90) were associated with lower failure.</p><p><strong>Conclusion: </strong>This large multicenter cohort highlights increasing host complexity, shifting microbiology, and predictors of failure, emphasizing the importance of early risk stratification and tailored strategies, such as multidisciplinary evaluation and close follow-up of high-risk patients to improve outcomes.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Infectious Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1